Childbirth monitoring technology has barely changed since the 1960s

From Prof. Jonathan Morris, VitalTrace - Chief Medical Officer

I had the wonderful opportunity to present VitalTrace’s pre-clinical data in the highly regarded Society for Maternal-Fetal Medicine 2025 Pregnancy Meeting in Denver, Colorado. This is the premier pregnancy meeting in USA. Our abstract was one of the 104 selected for presentation out of more than 2,000 submitted speaking to the significance and magnitude of the accomplishments we have achieved.

SMFM was a great opportunity to connect with obstetricians allowing VitalTrace to build invaluable relationships with leading practitioners and forming alliances to prepare the company for future activity in the United States and beyond. There was very strong interest in DelivAssure from leaders in Boston, Washington, Texas, East Virginia, New York and Philadelphia amongst others.

Some particularly notable feedback:

From Dr Emily Reiff (Brigham and Women’s Hospital, Harvard Medical School),

“I was fascinated by your study of real-time fetal lactate monitoring and think that innovation like this is what is needed for effective intrapartum management.”
‍

From Dr Justin Lappen (Cleveland Clinic),

“The whole team thought that DelivAssure would assist with Class II CTG dilemmas.”

‍

It was reinvigorating to see such strong support for continuous lactate monitoring and reinforces our confidence to launch DelivAssure in the United States.

VitalTrace is proud to announce it is one of 9 WA innovators and start ups to have received support from the Western Australian government, under the Future Health Research and Innovation (FHRI) Fund.

The Innovation Seed Fund is intended to bridge the gap in access to early-stage funding for WA start-ups to be more competitive in securing follow-on funding and develop into sustainable businesses, create high-level health sector jobs and enhance the production/manufacturing capacity of WA.

This project will fund the development of a commercialisation ready and clinically compatible product to improve maternal and fetal health outcomes during childbirth.

Medical Research Minister Stephen Dawson said “[VitalTrace has] the potential to change lives, and this funding will help them secure capital and develop into sustainable businesses.”

Read more here

VitalTrace has officially commenced its participation in the Texas Medical Center Innovation (TMCi) 2025 HealthTech Accelerator. Out of over 120 global applicants, we are proud to be one of just 12 companies selected—and among a very small number of international participants.

TMC is the largest healthcare provider in the United States and one of the largest globally. This opportunity has already yielded significant gains for the company, deepening our understanding of the U.S. hospital landscape. Discussions with leading institutions highlighted a consistent drive to reduce caesarean section rates, driven by strong fiscal and clinical imperatives.

Obstetricians and healthcare executives were candid in their support, emphasizing the urgent need for improved diagnostic tools. They shared that legal settlements related to hypoxic-ischemic encephalopathy can exceed US$40 million in Texas—and even higher in states like Massachusetts—underscoring the critical importance of innovation in this space.

We are immensely proud of the team’s efforts in preparing the company for this milestone, and we are deeply encouraged by the warm and validating reception we received in the U.S. We look forward to continuing our participation and contributing meaningfully to the program.